Seroprevalence and risk factors for Human papillomavirus in Taiwan

I. J. Wang, R. Viscidi, K. C. Hwang, T. Y. Lin, C. J. Chen, L. M. Huang, H. H. Chen, C. J. Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The aim of the study was to tailor a future Human papillomavirus (HPV) vaccine campaign and to help perform early primary prevention of HPV infection in Taiwan, where the incidence of cervical cancer is high. A cross-sectional survey was conducted of 826 female students, ages 10, 13, 16 and 19-22 years. A self-administered questionnaire was used to collect information on risk factors for HPV infection. Serum samples were tested for antibodies to HPV 16 capsids using a virus-like particle-based enzyme-linked immunosorbence assay. The age-adjusted odds ratio of HPV seropositivity was calculated for each risk factor by multiple logistic regression analysis. HPV 16 antibodies were detected in 13 (1.6%) of 826 participants. The HPV 16 seroprevalence was 0.35% (1/ 287), 0.85% (2/235), 3.2% (6/185) and 3.4% (4/119), respectively, for age groups of 10, 13, 16 and 19-22 years. In the multiple regression analysis, the history of having sexual activity was the most significant risk predictor for HPV16 seropositivity. The seroprevalence of HPV16 increased dramatically among high school seniors and university students, and was significantly associated with sexual activity. Vaccination against HPV is suggested to be undertaken in early adolescence, before 16 years of age and prior to sexual debut.

Original languageEnglish
Pages (from-to)14-18
Number of pages5
JournalJournal of Tropical Pediatrics
Volume54
Issue number1
DOIs
Publication statusPublished - Feb 2008
Externally publishedYes

Fingerprint

Seroepidemiologic Studies
Taiwan
Human papillomavirus 16
Papillomavirus Infections
Sexual Behavior
Regression Analysis
Students
Papillomavirus Vaccines
Antibodies
Capsid
Primary Prevention
Uterine Cervical Neoplasms
Virion
Vaccination
Age Groups
Cross-Sectional Studies
Logistic Models
History
Odds Ratio
Incidence

Keywords

  • HPV 16
  • Risk factors
  • Seroprevalence
  • Vaccination

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Wang, I. J., Viscidi, R., Hwang, K. C., Lin, T. Y., Chen, C. J., Huang, L. M., ... Chen, C. J. (2008). Seroprevalence and risk factors for Human papillomavirus in Taiwan. Journal of Tropical Pediatrics, 54(1), 14-18. https://doi.org/10.1093/tropej/fmm062

Seroprevalence and risk factors for Human papillomavirus in Taiwan. / Wang, I. J.; Viscidi, R.; Hwang, K. C.; Lin, T. Y.; Chen, C. J.; Huang, L. M.; Chen, H. H.; Chen, C. J.

In: Journal of Tropical Pediatrics, Vol. 54, No. 1, 02.2008, p. 14-18.

Research output: Contribution to journalArticle

Wang, IJ, Viscidi, R, Hwang, KC, Lin, TY, Chen, CJ, Huang, LM, Chen, HH & Chen, CJ 2008, 'Seroprevalence and risk factors for Human papillomavirus in Taiwan', Journal of Tropical Pediatrics, vol. 54, no. 1, pp. 14-18. https://doi.org/10.1093/tropej/fmm062
Wang, I. J. ; Viscidi, R. ; Hwang, K. C. ; Lin, T. Y. ; Chen, C. J. ; Huang, L. M. ; Chen, H. H. ; Chen, C. J. / Seroprevalence and risk factors for Human papillomavirus in Taiwan. In: Journal of Tropical Pediatrics. 2008 ; Vol. 54, No. 1. pp. 14-18.
@article{c3f9b35788e74002824e459a03f84ab7,
title = "Seroprevalence and risk factors for Human papillomavirus in Taiwan",
abstract = "The aim of the study was to tailor a future Human papillomavirus (HPV) vaccine campaign and to help perform early primary prevention of HPV infection in Taiwan, where the incidence of cervical cancer is high. A cross-sectional survey was conducted of 826 female students, ages 10, 13, 16 and 19-22 years. A self-administered questionnaire was used to collect information on risk factors for HPV infection. Serum samples were tested for antibodies to HPV 16 capsids using a virus-like particle-based enzyme-linked immunosorbence assay. The age-adjusted odds ratio of HPV seropositivity was calculated for each risk factor by multiple logistic regression analysis. HPV 16 antibodies were detected in 13 (1.6{\%}) of 826 participants. The HPV 16 seroprevalence was 0.35{\%} (1/ 287), 0.85{\%} (2/235), 3.2{\%} (6/185) and 3.4{\%} (4/119), respectively, for age groups of 10, 13, 16 and 19-22 years. In the multiple regression analysis, the history of having sexual activity was the most significant risk predictor for HPV16 seropositivity. The seroprevalence of HPV16 increased dramatically among high school seniors and university students, and was significantly associated with sexual activity. Vaccination against HPV is suggested to be undertaken in early adolescence, before 16 years of age and prior to sexual debut.",
keywords = "HPV 16, Risk factors, Seroprevalence, Vaccination",
author = "Wang, {I. J.} and R. Viscidi and Hwang, {K. C.} and Lin, {T. Y.} and Chen, {C. J.} and Huang, {L. M.} and Chen, {H. H.} and Chen, {C. J.}",
year = "2008",
month = "2",
doi = "10.1093/tropej/fmm062",
language = "English",
volume = "54",
pages = "14--18",
journal = "Journal of Tropical Pediatrics",
issn = "0142-6338",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Seroprevalence and risk factors for Human papillomavirus in Taiwan

AU - Wang, I. J.

AU - Viscidi, R.

AU - Hwang, K. C.

AU - Lin, T. Y.

AU - Chen, C. J.

AU - Huang, L. M.

AU - Chen, H. H.

AU - Chen, C. J.

PY - 2008/2

Y1 - 2008/2

N2 - The aim of the study was to tailor a future Human papillomavirus (HPV) vaccine campaign and to help perform early primary prevention of HPV infection in Taiwan, where the incidence of cervical cancer is high. A cross-sectional survey was conducted of 826 female students, ages 10, 13, 16 and 19-22 years. A self-administered questionnaire was used to collect information on risk factors for HPV infection. Serum samples were tested for antibodies to HPV 16 capsids using a virus-like particle-based enzyme-linked immunosorbence assay. The age-adjusted odds ratio of HPV seropositivity was calculated for each risk factor by multiple logistic regression analysis. HPV 16 antibodies were detected in 13 (1.6%) of 826 participants. The HPV 16 seroprevalence was 0.35% (1/ 287), 0.85% (2/235), 3.2% (6/185) and 3.4% (4/119), respectively, for age groups of 10, 13, 16 and 19-22 years. In the multiple regression analysis, the history of having sexual activity was the most significant risk predictor for HPV16 seropositivity. The seroprevalence of HPV16 increased dramatically among high school seniors and university students, and was significantly associated with sexual activity. Vaccination against HPV is suggested to be undertaken in early adolescence, before 16 years of age and prior to sexual debut.

AB - The aim of the study was to tailor a future Human papillomavirus (HPV) vaccine campaign and to help perform early primary prevention of HPV infection in Taiwan, where the incidence of cervical cancer is high. A cross-sectional survey was conducted of 826 female students, ages 10, 13, 16 and 19-22 years. A self-administered questionnaire was used to collect information on risk factors for HPV infection. Serum samples were tested for antibodies to HPV 16 capsids using a virus-like particle-based enzyme-linked immunosorbence assay. The age-adjusted odds ratio of HPV seropositivity was calculated for each risk factor by multiple logistic regression analysis. HPV 16 antibodies were detected in 13 (1.6%) of 826 participants. The HPV 16 seroprevalence was 0.35% (1/ 287), 0.85% (2/235), 3.2% (6/185) and 3.4% (4/119), respectively, for age groups of 10, 13, 16 and 19-22 years. In the multiple regression analysis, the history of having sexual activity was the most significant risk predictor for HPV16 seropositivity. The seroprevalence of HPV16 increased dramatically among high school seniors and university students, and was significantly associated with sexual activity. Vaccination against HPV is suggested to be undertaken in early adolescence, before 16 years of age and prior to sexual debut.

KW - HPV 16

KW - Risk factors

KW - Seroprevalence

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=39049093340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049093340&partnerID=8YFLogxK

U2 - 10.1093/tropej/fmm062

DO - 10.1093/tropej/fmm062

M3 - Article

C2 - 17984124

AN - SCOPUS:39049093340

VL - 54

SP - 14

EP - 18

JO - Journal of Tropical Pediatrics

JF - Journal of Tropical Pediatrics

SN - 0142-6338

IS - 1

ER -